Pembrolizumab monotherapy for previously untreated advanced hepatocellular carcinoma: data from the open-label, phase 2 KEYNOTE-224 trial

医学 耐受性 彭布罗利珠单抗 队列 内科学 索拉非尼 不利影响 临床终点 实体瘤疗效评价标准 肝细胞癌 耐火材料(行星科学) 外科 四分位间距 胃肠病学 肿瘤科
作者
Gontran Verset,Ivan Borbath,Mark Karwal,Chris Verslype,Hans Van Vlierberghe,Adel Kardosh,Vittorina Zagonel,Per Stål,Debashis Sarker,Daniel H Palmer,Arndt Vogel,Julien Edeline,Stephane Cattan,Masatoshi Kudo,Ann Li Cheng,Sadahisa Ogasawara,Bruno Daniele,Stephen L Chan,Jennifer J Knox,Shu-Kui Qin,Abby B Siegel,Michael Chisamore,Ken Hatogai,Anran Wang,Richard S. Finn,Andrew X. Zhu
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
标识
DOI:10.1158/1078-0432.ccr-21-3807
摘要

Abstract Purpose:KEYNOTE-224 cohort 1 demonstrated that pembrolizumab was efficacious and tolerable in patients with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib. We report results from KEYNOTE-224 (NCT02702414) cohort 2, which enrolled patients with aHCC and no prior systemic therapy. Experimental Design:KEYNOTE-224 was an open-label, multi-country phase 2 trial. Eligible patients in cohort 2 had aHCC not amenable or refractory to locoregional therapy and not previously treated with systemic therapy. Patients received pembrolizumab 200 mg intravenously every three weeks for {less than or equal to}2 years. Primary endpoint was objective response rate (ORR) by central imaging review per RECIST v1.1. Secondary endpoints included duration of response (DOR), disease control rate (DCR), time to progression (TTP), progression-free survival (PFS), overall survival (OS), and safety/tolerability. Results: Between Sept 4, 2018 and Feb 20, 2019, 51 patients were allocated in cohort 2. The median time from the first dose to data cutoff (Jan 19, 2021) was 27 months (range, 23-29). ORR was 16% (95% CI, 7-29) and was similar across key subgroups. Median DOR was 16 months (range, 3-24+), and DCR was 57%. The median PFS was 4 months (95% CI, 2-8), and median TTP was 4 months (95% CI, 3-9). Median OS was 17 months (95% CI, 8-23). Grade {greater than or equal to}3 treatment-related adverse events occurred in 16% of patients. Conclusions:In patients with aHCC with no prior systemic therapy, pembrolizumab provided durable antitumor activity, promising OS, and had a safety profile consistent with previous observations. These findings support further evaluation of pembrolizumab-based regimens for HCC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
请叫我风吹麦浪应助hashtag采纳,获得10
刚刚
独特元蝶完成签到,获得积分20
刚刚
1秒前
ljy发布了新的文献求助10
1秒前
开心超人完成签到,获得积分10
1秒前
wxj发布了新的文献求助10
2秒前
小马甲应助1234采纳,获得10
2秒前
huang发布了新的文献求助10
2秒前
杜天豪发布了新的文献求助10
2秒前
陈平安发布了新的文献求助10
4秒前
宁语完成签到,获得积分10
4秒前
科研通AI5应助可耐的冰萍采纳,获得30
4秒前
4秒前
田様应助juanlin2011采纳,获得10
5秒前
汉堡包应助失眠的青寒采纳,获得10
5秒前
huiluowork发布了新的文献求助10
5秒前
Q11发布了新的文献求助10
5秒前
如意元霜发布了新的文献求助10
6秒前
独特元蝶发布了新的文献求助10
6秒前
黄老板完成签到,获得积分10
6秒前
Ava应助XiangLuo采纳,获得10
6秒前
9秒前
SciGPT应助dpp采纳,获得10
10秒前
陆上行舟应助sheep采纳,获得10
10秒前
科研通AI2S应助liezus采纳,获得10
10秒前
威武的匕完成签到,获得积分10
11秒前
11秒前
可爱的函函应助哒哒哒采纳,获得10
11秒前
11秒前
拼搏千风完成签到,获得积分20
12秒前
不搭发布了新的文献求助10
15秒前
剧院的饭桶完成签到,获得积分10
15秒前
星月相遂完成签到,获得积分10
16秒前
科研通AI5应助Q11采纳,获得10
17秒前
陈平安完成签到,获得积分10
18秒前
123发布了新的文献求助10
19秒前
遥辉发布了新的文献求助20
20秒前
20秒前
haha完成签到 ,获得积分10
21秒前
闪闪青雪完成签到,获得积分10
21秒前
高分求助中
Production Logging: Theoretical and Interpretive Elements 2700
Mechanistic Modeling of Gas-Liquid Two-Phase Flow in Pipes 2500
Kelsen’s Legacy: Legal Normativity, International Law and Democracy 1000
Handbook on Inequality and Social Capital 800
Conference Record, IAS Annual Meeting 1977 610
Interest Rate Modeling. Volume 3: Products and Risk Management 600
Interest Rate Modeling. Volume 2: Term Structure Models 600
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3546676
求助须知:如何正确求助?哪些是违规求助? 3123726
关于积分的说明 9356475
捐赠科研通 2822353
什么是DOI,文献DOI怎么找? 1551369
邀请新用户注册赠送积分活动 723332
科研通“疑难数据库(出版商)”最低求助积分说明 713721